RCUS
Arcus Biosciences, Inc.
Biotechnology · Healthcare · United States
18.19
close · 2026-10-30
value
45
cheaper than peers45
quality
11
stronger fundamentals11
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 3 years ago | 18.9% | 98 |
| cash flow yield, 1 year ago | -7.7% | 57 |
| earnings yield, 1 year ago | -17.3% | 47 |
| earnings yield, 3 years ago | -20.4% | 43 |
| earnings yield, 2 years ago | -22.8% | 42 |
| earnings yield, latest year | -18.1% | 42 |
| cash flow yield, 2 years ago | -14.4% | 38 |
| price to sales | 19.55× | 37 |
| price to book | 4.98× | 36 |
| cash flow yield, latest year | -21.2% | 33 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | -234.1% | 43 |
| debt to equity | 51.3% | 30 |
| return on equity | -90.8% | 28 |
| revenue growth | -74.4% | 10 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | -$270.6M |
| employees | 601 |
| first trade | 2018-03-15 |
| next earnings | 2026-11-04 |
| fundamentals updated | 2026-08-07 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -3.29 | -3.14 | -4.15 | -3.71 |
| free cash flow | -$484.0M | -$176.0M | -$330.0M | $432.0M |
| net income | -$353.0M | -$283.0M | -$307.0M | -$267.0M |
| revenue | $247.0M | $258.0M | $117.0M | $112.0M |
| unusual items | $0 | -$20.0M | $0 | $0 |